Loading...
•
Jun 30, 2023
Taysha Gene Therapies Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported financial results for Q2 2023, with a net loss of $24.6 million, or $0.38 per share. The company's cash and cash equivalents totaled $45.1 million as of June 30, 2023. A private placement financing is expected to result in gross proceeds of approximately $150 million, extending the cash runway into the third quarter of 2025.
Initial data from the first adult patient dosed in the REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated and demonstrated improvement in key efficacy measures.
The FDA cleared the IND application for TSHA-102 in pediatric patients with Rett syndrome.
A CTA was submitted to the U.K. MHRA for TSHA-102 in pediatric patients with Rett syndrome.
A private placement financing is expected to result in gross proceeds of approximately $150 million, extending cash runway into the third quarter of 2025.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Net proceeds from PIPE, along with existing cash and cash equivalents, extends cash runway into the third quarter of 2025